z-logo
Premium
Coating‐Sheddable CD44‐Targeted Poly( d , l ‐lactide‐ co ‐glycolide) Nanomedicines Fabricated by Using Photoclick‐Crosslinkable Surfactant
Author(s) -
Li Shuai,
Qiu Min,
Guo Jiakun,
Zhao Xiaofei,
Zhong Zhiyuan,
Deng Chao
Publication year - 2020
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0
ISSN - 2366-3987
DOI - 10.1002/adtp.201900160
Subject(s) - plga , hyaluronic acid , cd44 , pulmonary surfactant , drug delivery , chemistry , materials science , paclitaxel , nanoparticle , in vivo , docetaxel , targeted drug delivery , nanocarriers , nuclear chemistry , nanotechnology , cancer , in vitro , biochemistry , medicine , anatomy , microbiology and biotechnology , biology
Abstract Poly( d , l ‐lactide‐ co ‐glycolide) (PLGA)‐based nanotherapeutics are intensively employed for the treatment of various diseases, though they frequently suffer from stability, selectivity, and drug release problems. Here, a facile fabrication of coating‐sheddable CD44‐targeted PLGA nanoparticles using photoclick‐crosslinkable hyaluronic acid‐ graft ‐tetrazole (HA‐ g ‐Tet) as a surfactant followed by photoclick reaction with l ‐cystine dimethacrylamide (MA‐Cys‐MA) (X‐PHS@NPs) for targeted delivery of docetaxel (DTX) to breast tumors in vivo is reported. X‐PHS@NPs exhibit strong blue fluorescence and a size of 109 nm. DTX‐loaded X‐PHS@NPs (DTX‐X‐PHS@NPs), while stable at physiological conditions (pH 7.4, 37 °C), release about 76.6% DTX under 10  m glutathione conditions. DTX‐X‐PHS@NPs are potent toward CD44‐overexpressing MCF‐7 human breast cancer cells with a low IC 50 of 0.27 µg mL −1 . Interestingly, X‐PHS@NPs reveal excellent tumor penetration ability and DTX‐X‐PHS@NPs induce significantly more effective inhibition of MCF‐7 human breast tumors in nude mice than free DTX. These coating‐sheddable CD44‐targeted PLGA nanoparticles provide an interesting platform for cancer chemotherapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here